The European Commission has withdrawn Viatris' (VTRS) authorization to market arsenic trioxide in the European Union. This decision follows Viatris' strategic move to cease sales of the cancer treatment, a choice made for commercial considerations. Originally granted approval in 2020, the marketing rights were relinquished at the request of Mylan Ireland Limited, a subsidiary of Viatris.
https://www.gurufocus.com/news/2832649/viatris-vtrs-withdraws-european-marketing-of-cancer-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.